NCT00426608

To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.

Placebo-Controlled, Randomized, Blinded, Double-Dummy, Crossover Study to Investigate the Attenuation of ACTH Activation Induced by Metyrapone With a Single Dose of GSK561679 or Alprazolam in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

A study to investigate the effects GSK561679 on part of the body's system that controls the balance of many of the hormones (including cortisol).

Conditions

• Depressive Disorder and Anxiety Disorders

Interventions

Type	Name	Description
DRUG	metyrapone	Metyrapone will be available as 250 mg dose capsule.
DRUG	alprazolam	Alprazolam capsules will be available with dose strength of 0.25mg
DRUG	placebo	GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.
DRUG	GSK561679	GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.

Timeline

• Start date: 2006-10-06
• Primary completion: 2007-01-08
• Completion: 2007-01-08
• First posted: 2007-01-25
• Last updated: 2017-09-11

Locations

1 site across 1 country: United Kingdom